HSBC/CALL/MODERNA/250/0.1/15.01.25 | Market Closed - Bid/Ask 19:35:43 24/05/2024 BST | After market 19:56:43 | |||
| 1.03 EUR | +10.75% |
|
1.05 | +1.94% |
| Current month | +639.44% | ||
| 1 month | +683.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 1.03 | +10.75% |
| 23/05/24 | 0.93 | +2.20% |
| 22/05/24 | 0.91 | +133.33% |
| 21/05/24 | 0.39 | +11.43% |
| 20/05/24 | 0.35 | +45.83% |
Real-time Boerse Frankfurt Warrants
Last update May 24, 2024 at 07:35 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807L |
| ISIN | DE000HG807L1 |
| Date issued | 02/02/2023 |
| Strike | 250 $ |
| Maturity | 15/01/2025 (236 Days) |
| Parity | 10 : 1 |
| Emission price | 3.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.38 € |
|---|---|
| Lowest since issue | 0.054 € |
| Spread | 0.02 € |
| Spread % | 1.89% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
164
USD
Average target price
138.5
USD
Spread / Average Target
-15.55%
- Stock Market
- Warrants
- Warrant
